Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Friday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of Enzo Biochem stock remained flat at $1.04 during trading on Friday. 194,009 shares of the stock were exchanged, compared to its average volume of 98,862. Enzo Biochem has a one year low of $0.99 and a one year high of $1.50. The stock’s 50-day moving average is $1.13 and its two-hundred day moving average is $1.12.

Enzo Biochem Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 15th will be paid a dividend of $0.10 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.40 annualized dividend and a dividend yield of 38.46%.

Institutional Trading of Enzo Biochem

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after buying an additional 11,742 shares in the last quarter. BBR Partners LLC bought a new position in shares of Enzo Biochem in the 3rd quarter worth approximately $112,000. XTX Topco Ltd lifted its stake in shares of Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares in the last quarter. Institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.